Rituxirel 500 mg Injection Supplier USA | Pharmaceutical Exporter from India

Rituxirel 500 mg Injection: Precision B-Cell Depletion for Advanced Hematology and Autoimmune Care

Are you seeking a trusted Rituxirel 500 mg injection exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a high-authority global supplier and bulk distributor of advanced monoclonal antibodies. We provide a specialized, cold-chain-integrated supply chain serving the USA, UK, Australia, and South Africa, ensuring that critical Rituximab therapies reach medical centers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Rituxirel 500 mg?

Rituxirel 500 mg Injection is a therapeutic chimeric monoclonal antibody containing the active ingredient Rituximab. Manufactured by Reliance Life Sciences, Rituxirel is a high-quality biosimilar designed to provide clinical efficacy and safety equivalent to the reference product Rituxan/MabThera.

For international B2B procurement, Rituxirel 500 mg (supplied as 500 mg/50 ml in a single-dose vial) is a cornerstone in the treatment of various B-cell malignancies and severe autoimmune disorders.

Primary Therapeutic Indications

Rituxirel 500 mg is clinically utilized for the following:

1. Non-Hodgkin Lymphoma (NHL): Including Follicular Lymphoma and Diffuse Large B-Cell Lymphoma (DLBCL).

2. Chronic Lymphocytic Leukemia (CLL): In combination with chemotherapy for previously untreated and treated patients.

3. Rheumatoid Arthritis (RA): For adult patients who have had an inadequate response to TNF-antagonist therapies.

4. Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA): Managing severe vascular inflammation.

5. Pemphigus Vulgaris (PV): An autoimmune condition causing severe skin and mucous membrane blistering.

Mechanism of Action: Targeted CD20 Binding

Rituxirel works through a multifaceted immunological process to deplete specific B-cells:

• CD20 Antigen Targeting: Rituximab binds specifically to the CD20 antigen, a protein found on the surface of pre-B and mature B-lymphocytes.

• Immune Effector Recruitment: Once bound, the antibody acts as a "bridge," recruiting the body's immune system to destroy the target cell via:

  • Antibody-Dependent Cellular Cytotoxicity (ADCC): Natural killer (NK) cells and macrophages release enzymes to lyse the B-cell.

  • Complement-Dependent Cytotoxicity (CDC): Triggering the complement cascade to form a membrane attack complex.

  • Apoptosis Induction: Directly signaling the cell to undergo programmed cell death.

• Sparing Stem Cells: Because CD20 is not expressed on hematopoietic stem cells, the body can regenerate healthy B-cells after treatment.

Administration and Clinical Safety

• Infusion Method: Must be administered as an intravenous (IV) infusion by qualified medical staff. It is not for IV bolus or push.

• Pre-medication: Standard protocol includes acetaminophen and an antihistamine to reduce the risk of infusion-related reactions.

• Cold-Chain Management: Requires strict storage at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze or shake.

• Key Monitoring: * Hepatitis B Reactivation: Screening is mandatory before therapy.

  • Infusion Reactions: Monitoring is most critical during the first 30–120 minutes of the first dose.

  • CBC Counts: Regular blood tests are required to monitor for neutropenia or lymphopenia.

Why Source Rituxirel from Ernest Oncology?

• Authentic Indian Exporter: Direct access to genuine Reliance Life Sciences inventory, ensuring 100% product authenticity and competitive wholesale pricing.

• Validated Cold-Chain Export: We use advanced thermal packaging and real-time monitoring to ensure Rituximab stability during transit to the USA, UK, Australia, and South Africa.

• Global Compliance: We provide full B2B documentation, including GMP compliance, batch-specific COAs, and necessary export permits.

• Bulk Supply Stability: We specialize in fulfilling large-scale orders for hospital groups, government tenders, and regional oncology distributors.